泰地唑胺对美欧医院骨关节感染革兰阳性菌的体外活性(2014-17)
该研究用微量肉汤稀释法检测泰地唑胺对2014-2017年美国与欧洲医院连续收集的797株骨关节感染革兰阳性菌的体外活性,并按CLSI与EUCAST标准判读。金黄色葡萄球菌最常见(59.3%),MRSA占29.6%,泰地唑胺对金黄色葡萄球菌MIC50/90为0.12/0.25 mg/L且100%敏感。结论为泰地唑胺对成人与儿童骨关节感染革兰阳性球菌具强效体外活性。
要点
- 金黄色葡萄球菌占骨关节感染分离株59.3%,其中MRSA占29.6%。
- 泰地唑胺对金黄色葡萄球菌MIC50/90为0.12/0.25 mg/L,100%敏感。
- 按MIC90比较,泰地唑胺比利奈唑胺强4-8倍。
核心结论
- 泰地唑胺对美欧医院成人与儿童骨关节感染相关革兰阳性球菌具有强效体外活性。
研究设计与样本
- 体外药敏研究,检测2014-2017年美国与欧洲医院连续收集的797株骨关节感染革兰阳性菌。
- 采用微量肉汤稀释法,遵循现行CLSI指南,并用CLSI与EUCAST折点判读。
主要发现
- 金黄色葡萄球菌占59.3%(美国58.6%、欧洲60.4%),MRSA率为29.6%,泰地唑胺MIC50/90为0.12/0.25 mg/L,100%敏感。
- 凝固酶阴性葡萄球菌占成人骨关节感染15.0%、儿童<5%,泰地唑胺MIC50/90为0.12/0.12 mg/L,99.1%敏感。
- 泰地唑胺对所有链球菌和肠球菌的MIC50/90为0.12/0.25 mg/L。
- 万古霉素、达托霉素和利奈唑胺总体敏感率>95%;按MIC90,泰地唑胺(0.12-0.25 mg/L)比利奈唑胺(0.5-2 mg/L)强4-8倍。
临床怎么用
- 提示泰地唑胺对骨关节感染常见革兰阳性球菌体外活性强,但本研究为体外药敏,未提供临床疗效数据。
局限性
- 仅报告体外药敏结果,未纳入临床结局或疗效评价。
- 分离株来自美国与欧洲医院,未报告其他地区数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite the advances in current healthcare, bone and joint infections (BJIs) are a major clinical challenge that frequently involve prolonged systemic antibiotic use. Healthcare providers consider tedizolid an attractive candidate for therapy in adults and children with BJI. OBJECTIVES: We tested tedizolid against a US and European collection of Gram-positive BJI isolates (n = 797) consecutively collected from 2014 to 2017. METHODS: Organisms were tested by broth microdilution susceptibility methods following current CLSI guidelines and interpreted by both CLSI and EUCAST breakpoint criteria. RESULTS: Staphylococcus aureus (59.3%; 58.6% in the USA and 60.4% in Europe) was the most common pathogen with a 29.6% MRSA rate and tedizolid MIC50/90 of 0.12/0.25 mg/L (100% susceptible). CoNS (15.0% of BJI in adults and <5% in children) had tedizolid MIC50/90 values of 0.12/0.12 mg/L (99.1% susceptible). Tedizolid exhibited MIC50/90 values of 0.12/0.25 mg/L for all streptococci and enterococci. Overall, high susceptibility rates (>95%) for vancomycin, daptomycin and linezolid were observed and, based on MIC90 values, tedizolid (MIC90 0.12-0.25 mg/L) was 4- to 8-fold more potent than linezolid (MIC90 0.5-2 mg/L) against this collection of Gram-positive pathogens causing BJI. CONCLUSIONS: This study showed that tedizolid had potent in vitro activity against contemporary Gram-positive cocci causing BJI in adults and children in US and European hospitals.
引用
- Carvalhaes CG, Sader HS, Flamm RK, et al. Tedizolid in vitro activity against Gram-positive clinical isolates causing bone and joint infections in hospitals in the USA and Europe (2014-17). J Antimicrob Chemother. 2019. PMID: 30932152. doi:10.1093/jac/dkz120
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。